The combined effect of vitamin D and zinc on premenstrual syndrome

The combined effect of vitamin D and Zinc on symptoms of depression, anxiety, premenstrual syndrome (PMS) and Total antioxidant capacity (TAC) in people with premenstrual syndrome (PMS): a randomized, Three-blind clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090901002394N47

Enrollment

Registered

2023-06-27

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenstrual Syndrome (PMS). Premenstrual tension syndrome

Interventions

Intervention 1: intervention group : In this group, 48 people with premenstrual syndrome take a vitamin D supplement of 2000 units and a zinc supplement in the form of zinc gluconate tablets containin

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Single women with a regular menstrual cycle between 24 and 35 days The suitable age for the study is 18-30 years old BMI of the studied women is between 18.5 and 24.9 Not taking any contraceptive pills Not taking anti-inflammatory, anti-depressant and psychotic drugs Not doing sports professionally Not taking vitamin D and zinc supplements for 3 months before starting the study Willingness, satisfaction and ability to carry out and complete the study and cooperate with the research

Exclusion criteria

Exclusion criteria: Being married Having vitamin D deficiency Suffering from an endocrine disorder such as thyroid failure, polycystic ovary syndrome and diabetes mellitus History of gynecological disorders History of autoimmune diseases Suffering from chronic and acute diseases (acute or chronic kidney failure, acute or chronic liver failure, chronic inflammatory disease or any known malignancy) Having irregular menstrual cycles (Less than 24 days and more than 35) Having stress caused by the death of relatives, surgery or marriage in the previous three months History of psychiatric diseases

Design outcomes

Primary

Measure	Time frame
Depression score in Beck's Depression Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck's Depression Inventory.;Depression score in Beck Anxiety Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck Anxiety Inventory.;The score of The premenstural symptoms screening tool (PSST). Timepoint: At baseline and after8 weeks. Method of measurement: The premenstural symptoms screening tool (PSST).;The levels of total antioxidant capacity. Timepoint: At baseline and after8 weeks. Method of measurement: ELISA Kit.	—

Measure

Time frame

Depression score in Beck's Depression Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck's Depression Inventory.;Depression score in Beck Anxiety Inventory. Timepoint: At baseline and after8 weeks. Method of measurement: Beck Anxiety Inventory.;The score of The premenstural symptoms screening tool (PSST). Timepoint: At baseline and after8 weeks. Method of measurement: The premenstural symptoms screening tool (PSST).;The levels of total antioxidant capacity. Timepoint: At baseline and after8 weeks. Method of measurement: ELISA Kit.

—

Secondary

Measure	Time frame
Weight. Timepoint: At baseline and after8 weeks. Method of measurement: Scale.;Body mass index. Timepoint: At baseline and after8 weeks. Method of measurement: Calculation.;Waist circumference. Timepoint: At baseline and after8 weeks. Method of measurement: Measuring tape.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Esmailpour

Iran University of Medical Sciences

esmailpour.zahraa@gmail.com+98 21 5526 1111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026